- Oragenics (OGEN, Financial) is set to participate in the 15th Annual Traumatic Brain Injury Conference in Boston from May 5-6, 2025.
- Dr. W. Frank Peacock, representing Oragenics, will present the latest updates on the HeadSMART II trial.
- The collaborative trial with BrainBox Solutions expects to enroll over 2,000 patients in a year.
Oragenics, Inc. (OGEN), a biotechnology company specializing in intranasal therapies for brain-related conditions, has announced its upcoming participation in the 15th Annual Traumatic Brain Injury Conference, scheduled for May 5-6, 2025, in Boston, MA. The conference is hosted by Arrowhead Sci-Tech Conferences & Events and will bring together leaders from academia, industry, government, and military sectors to discuss advancements in TBI research and clinical care.
Chief Clinical Officer of Oragenics, Dr. W. Frank Peacock, will present "An Update on HeadSMART II: Advancing Precision Strategies for Traumatic Brain Injury Detection and Management." This presentation will showcase data from HeadSMART II, which is one of the largest ongoing U.S. emergency department prospective biomarker discovery trials for mild traumatic brain injury (mTBI). The study, conducted in collaboration with BrainBox Solutions, aims to enroll over 2,000 patients within the next year.
Oragenics' partnership with BrainBox Solutions focuses on developing a comprehensive test-to-treat platform for mTBI. This platform combines BrainBox’s advanced diagnostic technologies with Oragenics’ intranasal therapeutic candidate, ONP-002. The findings from the HeadSMART II trial are expected to significantly influence the understanding and management of the mTBI population and shape future clinical trial strategies.
For further details about the conference, visit the official conference website. For more information on Oragenics and its initiatives, visit the company's website.
